Literature DB >> 8381046

Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein.

P C Adamson1, J F Boylan, F M Balis, R F Murphy, K A Godwin, L J Gudas, D G Poplack.   

Abstract

A study of chronic i.v. dosing of all-trans-retinoic acid (all-trans-RA) was performed to determine whether induction of the capacity-limited elimination process for all-trans-RA occurred with long-term drug administration. Because up-regulation of the cellular retinoic acid-binding proteins (CRABP) may act to bind all-trans-RA intracellularly, the amount of CRABP in skin biopsy samples obtained during and following the course of all-trans-RA administration was also determined. Four adult rhesus monkeys received 50 mg/m2 of all-trans-RA by bolus i.v. injection daily for 8 consecutive days and again for one additional dose following a 7-day period without drug. The plasma disappearance curve of all-trans-RA was characterized by a plateau phase, the duration of which decreased during the period of chronic drug administration, followed by a terminal exponential decay phase, which is consistent with a capacity-limited (saturable) elimination process. The Vmax of this process increased from 0.06 mumol/min on the first day to 0.17 mumol/min by the eighth day of all-trans-RA administration, consistent with induction of an enzymatic process. The amount of CRABP measured in skin biopsy specimens was rapidly induced, increasing to approximately 3-fold baseline levels by day 3 of all-trans-RA administration. It remained at this level throughout the period of chronic drug administration but diminished following the 7-day period without drug. These findings suggest that an intermittent schedule of administration for all-trans-RA has potential advantages over a continuous administration schedule. A period of time without drug administration would allow for return of plasma drug clearance toward baseline levels and down-regulation of CRABP, which could result in higher plasma drug concentrations and possibly less cytoplasmic binding of drug.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381046

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.

Authors:  A V Boddy; M Cole; A D Pearson; J R Idle
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 2.  Clinical pharmacokinetics of tretinoin.

Authors:  M B Regazzi; I Iacona; C Gervasutti; M Lazzarino; S Toma
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

3.  Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.

Authors:  David Sanford; Francesco Lo-Coco; Miguel A Sanz; Eros Di Bona; Steven Coutre; Jessica K Altman; Meir Wetzler; Steven L Allen; Farhad Ravandi; Hagop Kantarjian; Jorge E Cortes
Journal:  Br J Haematol       Date:  2015-07-24       Impact factor: 6.998

4.  Modulation of all-trans retinoic acid pharmacokinetics by liarozole.

Authors:  V A Miller; J R Rigas; J R Muindi; W P Tong; E Venkatraman; M G Kris; R P Warrell
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Mesenchymal stem cells induce granulocytic differentiation of acute promyelocytic leukemic cells via IL-6 and MEK/ERK pathways.

Authors:  Fang Chen; Kang Zhou; Lei Zhang; Fengxia Ma; Dandan Chen; Junjie Cui; Xiaoming Feng; Shaoguang Yang; Ying Chi; Zhibo Han; Feng Xue; Lijuan Rong; Meili Ge; Li Wan; Shuxia Xu; Wenjing Du; Shihong Lu; Hongying Ren; Zhongchao Han
Journal:  Stem Cells Dev       Date:  2013-03-15       Impact factor: 3.272

6.  Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off.

Authors:  M B Regazzi; D Russo; I Iacona; S Sacchi; G Visani; M Lazzarino; G Avvisati; P G Pelicci; G Dastoli; C Grandi; S Spreafico; R Grattoni; P Galieni; S Rupoli; A M Maiolo; E Guerra; A M Liberati
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

7.  Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group.

Authors:  G J Veal; M Cole; J Errington; A D J Pearson; A B M Foot; G Whyman; A V Boddy
Journal:  Br J Cancer       Date:  2007-01-16       Impact factor: 7.640

8.  The Effect of Bone Marrow Mesenchymal Stem Cells on the Granulocytic Differentiation of HL-60 Cells.

Authors:  Hossein Nikkhah; Elham Safarzadeh; Karim Shamsasenjan; Mehdi Yousefi; Parisa Lotfinejad; Mehdi Talebi; Mozhde Mohammadian; Farhoud Golafshan; Aliakbar Movassaghpour
Journal:  Turk J Haematol       Date:  2017-06-13       Impact factor: 1.831

9.  Identification and characterization of a phenyl-thiazolyl-benzoic acid derivative as a novel RAR/RXR agonist.

Authors:  Chie Koshiishi; Takanori Kanazawa; Eric Vangrevelinghe; Toshiyuki Honda; Shinji Hatakeyama
Journal:  Heliyon       Date:  2019-11-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.